Target Name: CDC34
NCBI ID: G997
Review Report on CDC34 Target / Biomarker Content of Review Report on CDC34 Target / Biomarker
CDC34
Other Name(s): ubiquitin-protein ligase R1 | Ubiquitin-conjugating enzyme E2-32 kDa complementing | (E3-independent) E2 ubiquitin-conjugating enzyme R1 | cell division cycle 34 homolog | Ubiquitin carrier protein | Ubiquitin-conjugating enzyme E2-32 KDA complementing | E2 ubiquitin-conjugating enzyme R1 | UBC3 | Ubiquitin-conjugating enzyme E2-CDC34 | UBE2R1 | Ubiquitin-conjugating enzyme E2 R1 | UB2R1_HUMAN | UBCH3 | Ubiquitin-protein ligase R1 | cell division cycle 34, ubiqiutin conjugating enzyme | ubiquitin carrier protein | E2-CDC34 | ubiquitin-conjugating enzyme E2-CDC34 | Cell division cycle 34, ubiqiutin conjugating enzyme | ubiquitin-conjugating enzyme E2-32 KDA complementing

Unlocking The Potential of CDC34: A Promising Drug Target for Neurodegenerative Disorders

Unlocking the Potential of CDC34: A promising Drug Target and Biomarker for the Treatment of Neurodegenerative Disorders

Neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's have a significant impact on the quality of life of millions of people worldwide. These conditions are characterized by the progressive loss of brain cells, leading to a range of symptoms such as memory loss, cognitive decline, and behavioral changes. Despite advances in neuroimaging and disease management, there is currently no cure for these debilitating conditions. Therefore, the development of new therapeutic strategies to treat neurodegenerative diseases remains a major focus of research.

One potential drug target that has received significant attention in recent years is CDC34, a protein known to be involved in the ubiquitin-protein ligase (UPL) system. In this article, we will explore the biology of CDC34 and its potential as a drug target and biomarker for the treatment of neurodegenerative diseases.

The UPL System

The ubiquitin-protein ligase (UPL) system is a complex protein-protein interaction network that plays a crucial role in the regulation of protein stability and localization in the cells. The UPL system consists of several key components, including the protein Ubiquitin (U), which is the most well-known protein in the system, and the protein Proteasome, which is the main protein involved in protein degradation.

UPL activity is regulated by multiple factors, including the concentration of ubiquitin and the presence of specific ubiquitin-like proteins (UPLs). One of the most well-studied UPLs is CDC34, which is characterized by its unique structure and function.

CDC34 Structure and Function

CDC34 is a 21-kDa protein that is composed of a 191-amino acid residue protein and a 20-amino acid residue nucleotide-binding oligomer (NBO). The protein has a characteristic Rossmann-fold, which is a type of secondary structure that is formed by the hydrophobic alignment of multiple amino acid residues. This unique structure allows CDC34 to interact strongly with other proteins, including UPLs, and enables it to participate in a wide range of cellular processes.

CDC34 functions as an essential protein of the UPL system by participating in the regulation of protein stability and localization. Specifically, CDC34 functions as a negative regulator of the UPL activity by interacting with the protein Ubiquitin and preventing it from forming a covalent complex with the target protein. This interaction between CDC34 and Ubiquitin plays a crucial role in the regulation of protein stability and localization, as well as in the development of neurodegenerative diseases.

CDC34 as a Drug Target

The potential of CDC34 as a drug target has been investigated extensively in recent years. Studies have shown that blocking CDC34 activity can significantly improve the stability and localization of target proteins, leading to improved cognitive function and reduced neurodegeneration.

One of the most promising strategies for targeting CDC34 is the use of small molecules, such as inhibitors or modulators of the UPL system. These small molecules can interact with CDC34 and prevent it from forming a covalent complex with its target protein.

An inhibitor of CDC34, called Ubiquitin-protein ligase 3 (UPL-3), has been shown to significantly reduce the levels of neurodegenerate proteins in rat models of Alzheimer's disease. UPL-3 works by binding to CDC34 and preventing it from forming a covalent complex with target proteins, leading to improved cognitive function and reduced neurodegeneration.

Another promising strategy for targeting CDC34 is the use of RNA-based therapeutics. For example, a small RNA (siRNA

Protein Name: Cell Division Cycle 34, Ubiqiutin Conjugating Enzyme

Functions: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-48'-linked polyubiquitination (PubMed:22496338). Cooperates with the E2 UBCH5C and the SCF(FBXW11) E3 ligase complex for the polyubiquitination of NFKBIA leading to its subsequent proteasomal degradation. Performs ubiquitin chain elongation building ubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin. UBE2D3 acts as an initiator E2, priming the phosphorylated NFKBIA target at positions 'Lys-21' and/or 'Lys-22' with a monoubiquitin. Cooperates with the SCF(SKP2) E3 ligase complex to regulate cell proliferation through ubiquitination and degradation of MYBL2 and KIP1. Involved in ubiquitin conjugation and degradation of CREM isoform ICERIIgamma and ATF15 resulting in abrogation of ICERIIgamma- and ATF5-mediated repression of cAMP-induced transcription during both meiotic and mitotic cell cycles. Involved in the regulation of the cell cycle G2/M phase through its targeting of the WEE1 kinase for ubiquitination and degradation. Also involved in the degradation of beta-catenin. Is target of human herpes virus 1 protein ICP0, leading to ICP0-dependent dynamic interaction with proteasomes (PubMed:10329681, PubMed:10373550, PubMed:10871850, PubMed:11675391, PubMed:12037680, PubMed:15652359, PubMed:17461777, PubMed:17698585, PubMed:19112177, PubMed:19126550, PubMed:19945379, PubMed:20061386, PubMed:20347421)

The "CDC34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3